Stocks · News reference
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses of $(0.09) per
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wolfe Research Initiates Coverage On Taysha Gene Therapies with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform rating.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies granted five new employees 314,000 RSUs and options to purchase 92,400 shares as inducement for employment. The RSUs vest over four years, while stock options have a $5.70 exercise price and 10-year term with four-year vesting schedule.
Taysha Gene Therapies shares are trading lower after the company reported worse-than-expected Q2 EPS results.